Literature DB >> 703854

Inhibition of the in vivo biosynthesis and changes of catecholamine levels in rat brain after alpha-methyl-p-tyrosine; time- and dose-response relationships.

E Widerlöv, T Lewander.   

Abstract

Male Sprague-Dawley rats were given 0.407 mmoles/kg of D,L-alpha-methyl-p-tyrosine methylester HCl (H44/68; alpha-MT) at eleven time-points between 0--24 h, or 8 doses between 0.013--1.628 mmoles/kg of the drug at 1 h before i.v. injection of 160 micronCi tyrosine-2,6-3H. The rats were killed 15 min after tyrosine-3H and brain alpha-MT, tyrosine and catecholamines (endogenous and labelled), and plasma alpha-MT and tyrosine (--3H) were chromatographically isolated before being assayed spectrophotofluorimetrically (endogenous) or by liquid scintillation methods (labelled compounds). A delayed penetration of alpha-MT from plasma into brain, different elimination rates of alpha-MT in plasma and brain, and decreasing brain/plasma drug concentration on increasing alpha-MT dosages, indicated, that alpha-MT in brain and plasma belong to different pharmacokinetic compartments. The endogenous levels of catecholamines in the time-response experiments, declined to a minimum 4 h after alpha-MT administration, where the dopamine level was 38% and the noradrenaline level 51% of the saline controls. Kinetic data of the catecholamine elimination is given. In the dose-response experiment the decrease in the endogenous catecholamine levels was dose-related up to 0.407 mmoles/kg of alpha-MT, with no further decline on higher doses. The maximal inhibition of brain catecholamine synthesis occurred within 30 min after alpha-MT administration and the inhibition correlated better with the brain than with plasma alpha-MT content. The inhibition was dose-related with a maximal synthesis inhibition of 95% for dopamine and 80% for noradrenaline at the highest dose of alpha-MT. The duration of synthesis inhibition and storage depletion were shorter for noradrenaline (12 h) than for dopamine (16 h). Further, the ED50 for synthesis inhibition of dopamine (0.057 mmoles/kg) was half of the ED50 for synthesis inhibition of noradrenaline (0.117 mmoles/kg). This might suggest different sensitivities towards alpha-MT or different availabilities of alpha-MT in the two neuron populations. At the three highest doses of alpha-MT there were signs of interference with the uptake process for tyrosine from plasma into the brain. This was indicated by increased plasma levels and decreased brain levels of tyrosine (--3H).

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 703854     DOI: 10.1007/bf00495547

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  54 in total

1.  Tyrosine hydroxylase inhibitors.

Authors:  K E Moore; J A Dominic
Journal:  Fed Proc       Date:  1971 May-Jun

2.  Effects of some psychotropic drugs on dopamine synthesis in the rat striatum.

Authors:  M J Besson; A Cheramy; J Glowinski
Journal:  J Pharmacol Exp Ther       Date:  1971-04       Impact factor: 4.030

3.  Some problems encountered in attempting to estimate catecholamine turnover using lbbelled tyrosine.

Authors:  T Persson; B Waldeck
Journal:  J Pharm Pharmacol       Date:  1970-07       Impact factor: 3.765

4.  The determination of dopamine by a modification of the dihydroxyindole fluorimetric assay.

Authors:  C V Atack
Journal:  Br J Pharmacol       Date:  1973-08       Impact factor: 8.739

5.  Subcellular localization of tyrosine hydroxylase in beef caudate nucleus.

Authors:  P L McGeer; S P Bagchi; E G McGeer
Journal:  Life Sci       Date:  1965-10       Impact factor: 5.037

6.  Effects of alpha-methyltyrosine on brain catecholamines and conditioned behavior in guinea pigs.

Authors:  K E Moore
Journal:  Life Sci       Date:  1966-01       Impact factor: 5.037

7.  Inhibitors of endogenous catecholamine biosynthesis.

Authors:  S Spector
Journal:  Pharmacol Rev       Date:  1966-03       Impact factor: 25.468

8.  Application of steady state kinetics to the estimation of synthesis rate and turnover time of tissue catecholamines.

Authors:  B B Brodie; E Costa; A Dlabac; N H Neff; H H Smookler
Journal:  J Pharmacol Exp Ther       Date:  1966-12       Impact factor: 4.030

9.  Catecholamines and mania: the effect of alpha-methyl-para-tyrosine on manic behavior and catecholamine metabolism.

Authors:  H K Brodie; D L Murphy; F K Goodwin; W E Bunney
Journal:  Clin Pharmacol Ther       Date:  1971 Mar-Apr       Impact factor: 6.875

10.  Brain catechol synthesis: control by train tyrosine concentration.

Authors:  R J Wurtman; F Larin; S Mostafapour; J D Fernstrom
Journal:  Science       Date:  1974-07-12       Impact factor: 47.728

View more
  18 in total

1.  In vivo comparison of norepinephrine and dopamine release in rat brain by simultaneous measurements with fast-scan cyclic voltammetry.

Authors:  Jinwoo Park; Pavel Takmakov; R Mark Wightman
Journal:  J Neurochem       Date:  2011-10-20       Impact factor: 5.372

2.  Effects of alpha-methyl-p-tyrosine on monoamines and catecholamine receptors in rat cerebral cortex and neostriatum.

Authors:  Y Sauvé; T A Reader
Journal:  Neurochem Res       Date:  1988-09       Impact factor: 3.996

3.  Dopamine depletion attenuates some behavioral abnormalities in a hyperdopaminergic mouse model of bipolar disorder.

Authors:  Jordy van Enkhuizen; Mark A Geyer; Adam L Halberstadt; Xiaoxi Zhuang; Jared W Young
Journal:  J Affect Disord       Date:  2013-11-16       Impact factor: 4.839

4.  Reversible Pharmacological Induction of Motor Symptoms in MPTP-Treated Mice at the Presymptomatic Stage of Parkinsonism: Potential Use for Early Diagnosis of Parkinson's Disease.

Authors:  Gulnara R Khakimova; Elena A Kozina; Valerian G Kucheryanu; Michael V Ugrumov
Journal:  Mol Neurobiol       Date:  2016-05-19       Impact factor: 5.590

5.  Alpha-methyl-para-tyrosine pretreatment protects from striatal neuronal death induced by four-vessel occlusion in the rat.

Authors:  C Marie; C Mossiat; A Beley; J Bralet
Journal:  Neurochem Res       Date:  1992-10       Impact factor: 3.996

6.  Effects of centrally administered neuropeptide Y (NPY) and NPY13-36 on the brain monoaminergic systems of the rat.

Authors:  M Heilig; L Vècséi; C Wahlestedt; C Alling; E Widerlöv
Journal:  J Neural Transm Gen Sect       Date:  1990

7.  Persistent psychosis after reduction in pre- and post-synaptic dopaminergic function.

Authors:  A Wolkin; E Duncan; M Sanfilipo; S Wieland; T B Cooper; J Rotrosen
Journal:  J Neural Transm Gen Sect       Date:  1994

8.  Dose-dependent pharmacokinetics of alpha-methyl-p-tyrosine (alpha-MT) and comparison of catecholamine turnover rates after two doses of alpha-MT.

Authors:  E Widerlöv
Journal:  J Neural Transm       Date:  1979       Impact factor: 3.575

9.  Short-latency activation of striatal spiny neurons via subcortical visual pathways.

Authors:  Jan M Schulz; Peter Redgrave; Carsten Mehring; Ad Aertsen; Koreen M Clements; Jeff R Wickens; John N J Reynolds
Journal:  J Neurosci       Date:  2009-05-13       Impact factor: 6.167

10.  Evidence for monoaminergic involvement in triadimefon-induced hyperactivity.

Authors:  K M Crofton; V M Boncek; R C MacPhail
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.